Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy

Biogen

149.14 CHF -14.64%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy or IgAN, demonstrated substantial reductions in proteinuria, stabilization of kidney function, and a sustained treatment effect lasting more than 18 months after the last dose of felzartamab.

According to the company, the Phase 2 IGNAZ study (n=54) explored the efficacy and safety of felzartamab in patients with IgAN and high risk of progressive kidney dysfunction. With respect to efficacy, patients receiving a nine-dose regimen of felzartamab over a six-month treatment period experienced substantial reductions in proteinuria levels as assessed by the urinary protein:creatinine ratio (UPCR) and stabilization of kidney function, as measured by the estimated glomerular filtration rate (eGFR), through 24 months. Notably, patients maintained a mean reduction of approximately 50% in the UPCR through month 24, which was more than 18 months after the last dose was administered.

The results suggest that felzartamab may have the potential to preserve kidney function and be administered on treatment cycles instead of continuous dosing, the company said.

Further analysis revealed that felzartamab administration resulted in selective and durable reductions in IgA antibody levels, while IgG and IgM levels recovered to baseline 3 months off-treatment. This selective reduction may offer maintenance of significant immune functions essential for infection protection. Overall, administration of felzartamab was generally well tolerated with a safety profile consistent with prior studies.

For More Such Health News, visit rttnews.com.